Quantcast
Last updated on April 16, 2014 at 12:17 EDT

Latest Lipase Stories

2012-08-23 23:50:10

Enzymes involved in breaking down fat can now be manipulated to work three times harder by turning on a molecular switch recently observed by chemists at the University of Copenhagen. Being able to control this chemical on/off button could have massive implications for curing diseases related to obesity including diabetes, cardio vascular disease, stroke and even skin problems like acne. But the implications may be wider. Possibly the most important discovery in enzymology The results...

European Agency Recommends Gene Therapy Approval
2012-07-21 08:56:42

redOrbit Staff & Wire Reports - Your Universe Online A European Union agency for the evaluation of medicinal products is recommending the approval of a gene therapy treatment for a rare disease, which would be the first time a treatment of this kind has received the regulatory go-ahead for use in the West, according to various reports published Friday. A statement released by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) officially...

2012-07-20 02:22:06

AMSTERDAM, The Netherlands, July 20, 2012 /PRNewswire/ -- - First gene therapy in the Western world to reach important regulatory approval milestone, culminating 40 years of research - First therapy for LPL deficient patients, a severe disease with no alternative treatment - Validates uniQure's unique AAV-based gene therapy platform, consisting of a modular, plug-and-play vector system and unrivaled GMP manufacturing...

2011-07-08 00:00:00

AMSTERDAM, July 7, 2011 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has filed a request for re-examination of the Marketing Authorisation Application for Glybera(R)with the European Medicines Agency. Glybera is a gene therapy for the genetic disorder lipoprotein lipase deficiency. The Company expects that the re-examination of the dossier will be completed by the end of 2011. About...

2011-06-14 08:30:00

ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON(R) (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). The CREON 3,000 units of lipase capsule provides the lowest dosage strength in the class approved by the FDA. This new option will enable more precise dosing titration in accordance with the...

2011-05-20 00:00:00

AMSTERDAM, May 20, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein. Glybera is a gene therapy product under development for the treatment of...

2010-09-27 03:54:00

BILBAO, Spain, September 27, 2010 /PRNewswire-FirstCall/ -- - LPLchip(R) Rapidly and Precisely Detects Mutations Causing LPL Deficiency, a Cause of Acute Pancreatitis - LPLchip(R) Identifies Patients who Could Benefit From Gene Therapy, Such as AMT's Glybera(R), Currently Under Review for EU Approval Progenika Biopharma S.A., a pioneer in the field of personalized medicine, announced today that it has obtained the CE Mark allowing the sale in Europe of its LPLchip(R), the...

2010-07-07 16:51:53

New findings reported in the July issue of Cell Metabolism, a Cell Press publication, are offering new leads as to why some people might suffer from high levels of triglycerides. High triglycerides are a risk factor for atherosclerosis and cardiovascular disease. They can also lead to inflammation of the pancreas, the researchers said. The team led by Loren Fong and Stephen Young of the University of California, Los Angeles, has identified the component responsible for bringing a key...

2010-04-27 05:54:00

VIENNA, Austria, April 27, 2010 /PRNewswire/ -- EUCODIS Bioscience, a developer and manufacturer of customized enzymes, and Martin-Luther-University Halle-Wittenberg, Germany, (MLU), today announced a collaboration agreement for the characterization of novel lipases, phospholipases, and other enzymes that EUCODIS Bioscience is marketing or has under development. "Given the breadth of potential uses of our enzymes, we would like to provide our customers with comprehensive analytical...

2010-03-09 05:43:00

VIENNA, Austria, March 9, 2010 /PRNewswire/ -- EUCODIS Bioscience, a company providing customized enzymes to the pharmaceutical, chemical, and other industries, announced today that it has launched a panel of phospholipases, adding a new enzyme family to its product portfolio. Phospholipases are a group of enzymes that are widely used in the industrial processing of natural fats and oils, such as in the food and beverage industries, in the cosmetics industry, and in the manufacturing...